Enstilar价格一览

Enstilar is a specific drug for the treatment of plaque psoriasis. The price of its original drug and its domestic launch have attracted much attention. This article will provide a detailed analysis of Enstilar’s ​​price information, domestic launch progress and clinical efficacy to provide patients with a comprehensive medication reference.

Prices of Enstilar’s ​​original drug and generic drugs

Currently, only the original version of Enstilar is on the market globally, and no generic drugs have been approved. The following is a detailed analysis of the price of Enstilar.

Original drug price

The official price of the Enstilar original drug produced by Norway's LEO Pharma is US$188 per box (2 bottles*60g). This price may vary in different countries and regions, mainly affected by local tax policies and medical systems.

Price-affecting factors

Factors that affect the actual purchase price of Enstilar include exchange rates, international shipping costs, tariffs, service fees, etc. Some countries may also charge special import taxes on pharmaceuticals, causing overall prices to rise.

Current status of generic drugs

As of June 2025, no generic drug of Enstilar has been approved for marketing globally. Due to the patent protection period and technical threshold of the drug, it is expected that there will be no lower-priced substitute products in the short term.

Understanding the price structure of Enstilar can help patients budget for treatment and avoid economic losses caused by price information asymmetry.

Enstilar’s ​​domestic launch status

The launch of Enstilar in China has aroused the expectations of many psoriasis patients. The following is the latest progress of this drug in the country.

Approval Progress

Leo Pharma submitted a marketing authorization application for Enstilar to the Chinese Food and Drug Administration in January 2024. Previously, the enrollment of the first patient in China’s Phase III clinical trial was completed in July 2023.

Medical Insurance Situation

At present, Enstilar has not been included in China’s medical insurance catalog. It usually takes several years for a new drug to be approved for marketing and enter the medical insurance. Patients must be prepared to purchase the drug at their own expense.

Purchase Channels

Before it is officially approved for listing in China, Chinese patients can only obtain Enstilar through special channels such as overseas purchasing. It is recommended to choose purchase channels recommended by regular medical institutions to avoid the risk of counterfeit drugs.

Paying attention to the approval status of Enstilar in China can help patients obtain regular treatment drugs in a timely manner.

Efficacy of Enstilar

The unique formula of Enstilar gives it significant advantages in the treatment of psoriasis.

Mechanism of action

Enstilar contains two active ingredients: calcipotriol and betamethasone dipropionate, which act on vitamin D receptors and glucocorticoid receptors respectively, inhibiting abnormal skin proliferation and inflammatory reactions through dual mechanisms.

Clinical data

The clinical trials based on the FDA approval showed that after 4 weeks of treatment with Enstilar, the skin lesion area and severity index (PASI) of most patients improved, and long-term follow-up confirmed that its efficacy can last for more than ten weeks.

Usage recommendations

It is recommended to use it once a day for 4 consecutive weeks. Clinical observations show that most patients can see significant results within a few weeks, manifested by reduced erythema, reduced scaling, and improved skin thickness.

The remarkable efficacy of Enstilar provides a new treatment option for psoriasis patients, and its convenient foam dosage form further enhances the medication experience.